Calcium, Phosphate, and Magnesium Metabolism in Chronic Kidney Disease
Authors:
- Silvia FerrèSFSilvia Ferrè
- Javier A. NeyraJNJavier A. Neyra
- Orson W. MoeOMOrson W. Moe
- 1 January 2020
- book chapter
- Published by Elsevier
- p. 661-679
Abstract
No abstract availableKeywords
This publication has 138 references indexed in Scilit:
- Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate dietKidney International, 2012
- Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2012
- Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heartNature Communications, 2012
- Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivoBone, 2011
- Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitroKidney International, 2011
- Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney diseaseBone, 2009
- In vivo genetic evidence for klotho‐dependent, fibroblast growth factor 23 (Fgf23) ‐mediated regulation of systemic phosphate homeostasisThe FASEB Journal, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patientsKidney International, 2007
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004